About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 104315, 10 pages
http://dx.doi.org/10.1155/2013/104315
Review Article

Update on Anticytokine Treatment for Asthma

1Clinical Pharmacology Unit, Department of Health Science, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, Viale Europa-Località Germaneto, 88100 Catanzaro, Italy
2Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, Viale Europa-Località Germaneto, 88100 Catanzaro, Italy
3Department of Respiratory Medicine, University of Salerno, 84084 Fisciano (SA), Italy

Received 29 April 2013; Accepted 7 June 2013

Academic Editor: Alexandre Paula Rogerio

Copyright © 2013 Luca Gallelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. T. Holgate, H. S. Arshad, G. C. Roberts, P. H. Howarth, P. Thurner, and D. E. Davies, “A new look at the pathogenesis of asthma,” Clinical Science, vol. 118, no. 7, pp. 439–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. P. Anderson, “Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease,” The Lancet, vol. 372, no. 9643, pp. 1107–1119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Anandan, U. Nurmatov, O. C. P. Van Schayck, and A. Sheikh, “Is the prevalence of asthma declining? Systematic review of epidemiological studies,” Allergy, vol. 65, no. 2, pp. 152–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Masoli, D. Fabian, S. Holt, and R. Beasley, “The global burden of asthma: executive summary of the GINA dissemination committee report,” Allergy, vol. 59, no. 5, pp. 469–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. E. D. Bateman, H. A. Boushey, J. Bousquet et al., “Can guideline-defined asthma control be achieved? The gaining optimal asthma control study,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 8, pp. 836–844, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. C. H. Fanta, “Asthma,” The New England Journal of Medicine, vol. 360, no. 10, pp. 1002–1014, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L.-P. Boulet, “Influence of comorbid conditions on asthma,” European Respiratory Journal, vol. 33, no. 4, pp. 897–906, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Daoui, B. D'Agostino, L. Gallelli, X. E. Alt, F. Rossi, and C. Advenier, “Tachykinins and airway microvascular leakage induced by HCI intra-oesophageal instillation,” European Respiratory Journal, vol. 20, no. 2, pp. 268–273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Gallelli, B. D'Agostino, G. Marrocco et al., “Role of tachykinins in the bronchoconstriction induced by HCl intraesophageal instillation in the rabbit,” Life Sciences, vol. 72, no. 10, pp. 1135–1142, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. D'Agostino, G. Marrocco, M. De Nardo et al., “Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux,” British Journal of Pharmacology, vol. 144, no. 6, pp. 813–820, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Dolan, K. E. Fraher, E. R. Bleecker et al., “Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma,” Annals of Allergy, Asthma and Immunology, vol. 92, no. 1, pp. 32–39, 2004. View at Scopus
  12. G. Pelaia, A. Vatrella, L. Gallelli et al., “Respiratory infections and asthma,” Respiratory Medicine, vol. 100, no. 5, pp. 775–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Barnes, “The cytokine network in asthma and chronic obstructive pulmonary disease,” Journal of Clinical Investigation, vol. 118, no. 11, pp. 3546–3556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. D'Agostino, C. Advenier, R. De Palma et al., “The involvement of sensory neuropeptides in airway hyper-responsiveness in rabbits sensitized and challenged to Parietaria judaica,” Clinical and Experimental Allergy, vol. 32, no. 3, pp. 472–479, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Pelaia, G. Cuda, A. Vatrella et al., “Mitogen-activated protein kinases and asthma,” Journal of Cellular Physiology, vol. 202, no. 3, pp. 642–653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Pelaia, A. Vatrella, and R. Maselli, “The potential of biologics for the treatment of asthma,” Nature Reviews Drug Discovery, vol. 11, no. 12, pp. 958–972, 2012.
  17. P. M. Hansbro, G. V. Scott, A. T. Essilfie et al., “Th2 cytokine antagonists: potential treatments for severe asthma,” Expert Opinion on Investigational Drugs, vol. 22, no. 1, pp. 49–69, 2013.
  18. M. Caruso, E. Crisafulli, S. Demma, S. Holgate, and R. Polosa, “Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma,” Expert Opinion on Biological Therapy, vol. 13, no. 3, pp. 393–402, 2013.
  19. G. Pelaia, L. Gallelli, T. Renda et al., “Update on optimal use of omalizumab in management of asthma,” Journal Asthma Allergy, vol. 4, pp. 49–59, 2011.
  20. G. Pelaia, L. Gallelli, P. Romeo et al., “Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma,” International Journal of Clinical Pharmacology and Therapeutics, vol. 49, no. 12, pp. 713–721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. G. Holt and P. D. Sly, “Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis,” Chest, vol. 139, no. 5, pp. 1165–1171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. R. Murdoch and C. M. Lloyd, “Chronic inflammation and asthma,” Mutation Research, vol. 690, no. 1-2, pp. 24–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Hammad, M. Chieppa, F. Perros, M. A. Willart, R. N. Germain, and B. N. Lambrecht, “House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells,” Nature Medicine, vol. 15, no. 4, pp. 410–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. G. Woodruff, B. Modrek, D. F. Choy et al., “T-helper type 2-driven inflammation defines major subphenotypes of asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 5, pp. 388–395, 2009.
  25. C. M. Lloyd, “Dust mites' dirty dealings in the lung,” Nature Medicine, vol. 15, no. 4, pp. 366–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kitamura, K. Takeda, T. Koya et al., “Critical role of the Fc receptor γ-chain on APCs in the development of allergen-induced airway hyperresponsiveness and inflammation,” Journal of Immunology, vol. 178, no. 1, pp. 480–488, 2007. View at Scopus
  27. T. Kallinich, K. C. Beler, U. Wahn, P. Stock, and E. Hamelmann, “T-cell co-stimulatory molecules: their role in allergic immune reactions,” European Respiratory Journal, vol. 29, no. 6, pp. 1246–1255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. G. E. Kaiko, J. C. Horvat, K. W. Beagley, and P. M. Hansbro, “Immunological decision-making: how does the immune system decide to mount a helper T-cell response?” Immunology, vol. 123, no. 3, pp. 326–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. Y.-J. Liu, “Thymic stromal lymphopoietin: master switch for allergic inflammation,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 269–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Larché, D. S. Robinson, and A. B. Kay, “The role of T lymphocytes in the pathogenesis of asthma,” Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 450–463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. P. C. Fulkerson and M. E. Rothenberg, “Targeting eosinophils in allergy, inflammation and beyond,” Nature Reviews Drug Discovery, vol. 12, no. 2, pp. 117–129, 2013.
  32. G. E. Kaiko and P. S. Foster, “New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma,” Current Opinion in Allergy and Clinical Immunology, vol. 11, no. 1, pp. 39–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Cosmi, F. Liotta, E. Maggi, S. Romagnani, and F. Annunziato, “Th17 cells: new players in asthma pathogenesis,” Allergy, vol. 66, no. 8, pp. 989–998, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. J. Aujla and J. F. Alcorn, “TH17 cells in asthma and inflammation,” Biochimica et Biophysica Acta, vol. 1810, no. 11, pp. 1066–1079, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Al-Ramli, D. Préfontaine, F. Chouiali et al., “TH17-associated cytokines (IL-17A and IL-17F) in severe asthma,” Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1185–1187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Durrant and D. W. Metzger, “Emerging roles of T helper subsets in the pathogenesis of asthma,” Immunological Investigations, vol. 39, no. 4-5, pp. 526–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Zhao, J. Yang, Y.-D. Gao, and W. Guo, “Th17 immunity in patients with allergic asthma,” International Archives of Allergy and Immunology, vol. 151, no. 4, pp. 297–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. N. W. Lukacs, R. M. Strieter, S. W. Chensue, M. Widmer, and S. L. Kunkel, “TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation,” Journal of Immunology, vol. 154, no. 10, pp. 5411–5417, 1995. View at Scopus
  39. Y. Amrani, R. A. Panettieri Jr., N. Frossard, and C. Bronner, “Activation of the TNFα-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 1, pp. 55–63, 1996. View at Scopus
  40. R. H. Dougherty and J. V. Fahy, “Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype,” Clinical and Experimental Allergy, vol. 39, no. 2, pp. 193–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Contoli, S. D. Message, V. Laza-Stanca et al., “Role of deficient type III interferon-λ production in asthma exacerbations,” Nature Medicine, vol. 12, no. 9, pp. 1023–1026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Matsumoto, H. Inoue, S. Fukuyama et al., “Frequency of Foxp3+CD4+CD25+ T cells is associated with the phenotypes of allergic asthma,” Respirology, vol. 14, no. 2, pp. 187–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Provoost, T. Maes, Y. M. Van Durme et al., “Decreased FOXP3 protein expression in patients with asthma,” Allergy, vol. 64, no. 10, pp. 1539–1546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. M. Lloyd and E. M. Hessel, “Functions of T cells in asthma: more than just TH2 cells,” Nature Reviews Immunology, vol. 10, no. 12, pp. 838–848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. P. J. Barnes, “Intrinsic asthma: not so different from allergic asthma but driven by superantigens?” Clinical and Experimental Allergy, vol. 39, no. 8, pp. 1145–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Turato, A. Barbato, S. Baraldo et al., “Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 5, pp. 476–482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Bergeron, W. Al-Ramli, and Q. Hamid, “Remodeling in asthma,” Proceedings of the American Thoracic Society, vol. 6, no. 3, pp. 301–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S. T. Holgate, J. Holloway, S. Wilson, F. Bucchieri, S. Puddicombe, and D. E. Davies, “Epithelial-mesenchymal communication in the pathogenesis of chronic asthma,” Proc Am Thorac Soc, vol. 1, no. 2, pp. 93–98, 2004. View at Scopus
  49. T.-L. Hackett, S. M. Warner, D. Stefanowicz et al., “Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-β1,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 2, pp. 122–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. B. D'Agostino, L. Gallelli, M. Falciani et al., “Endothelin-1 induced bronchial hyperresponsiveness in the rabbit: an ET(A) receptor-mediated phenomenon,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 360, no. 6, pp. 665–669, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Rossi, L. Gallelli, G. Marrocco et al., “Ruolo dell’endotelina nell’apparato respiratorio,” Minerva Pneumologica, vol. 39, pp. 111–122, 2000.
  52. B. D'Agostino, C. Advenier, M. Falciani et al., “Endothelin-1 increases cholinergic nerve-mediated contraction of human bronchi via tachykinin synthesis induction,” British Journal of Pharmacology, vol. 134, no. 7, pp. 1447–1454, 2001. View at Scopus
  53. L. Gallelli, G. Pelaia, B. D'Agostino et al., “Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of map kinases,” Journal of Cellular Biochemistry, vol. 96, no. 4, pp. 858–868, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Pelaia, L. Gallelli, B. D'Agostino et al., “Effects of TGF-β and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts,” Journal of Cellular Physiology, vol. 210, no. 2, pp. 489–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. B. D'Agostino, F. Roviezzo, R. De Palma et al., “Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma,” Clinical and Experimental Allergy, vol. 37, no. 10, pp. 1436–1443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Gallelli, D. Falcone, G. Pelaia et al., “Interleukin-6 receptor superantagonist Sant7 inhibits TGF-β-induced proliferation of human lung fibroblasts,” Cell Proliferation, vol. 41, no. 3, pp. 393–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Pelaia, T. Renda, L. Gallelli et al., “Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma,” Respiratory Medicine, vol. 102, no. 8, pp. 1173–1181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. S. T. Holgate, “Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 495–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. C. G. Garlisi, T. T. Kung, P. Wang et al., “Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation,” American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 2, pp. 248–255, 1999. View at Scopus
  60. P. J. Mauser, A. M. Pitman, X. Fernandez et al., “Effects of an antibody to interleukin-5 in a monkey model of asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 2, pp. 467–472, 1995. View at Scopus
  61. N. A. Molfino, D. Gossage, R. Kolbeck, J. M. Parker, and G. P. Geba, “Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor,” Clinical and Experimental Allergy, vol. 42, no. 5, pp. 712–737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. M. J. Leckie, A. Ten Brinke, J. Khan et al., “Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response,” Lancet, vol. 356, pp. 2144–2148, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Flood-Page, C. Swenson, I. Faiferman et al., “A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1062–1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Haldar, C. E. Brightling, B. Hargadon et al., “Mepolizumab and exacerbations of refractory eosinophilic asthma,” The New England Journal of Medicine, vol. 360, no. 10, pp. 973–984, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Nair, M. M. M. Pizzichini, M. Kjarsgaard et al., “Mepolizumab for prednisone-dependent asthma with sputum eosinophilia,” The New England Journal of Medicine, vol. 360, no. 10, pp. 985–993, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. I. D. Pavord, S. Korn, P. Howarth et al., “Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial,” Lancet, vol. 380, no. 9842, pp. 651–659, 2012.
  67. M. Castro, S. Mathur, F. Hargreave et al., “Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 10, pp. 1125–1132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. W. W. Busse, R. Katial, D. Gossage et al., “Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma,” Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1237–1244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. C. K. Oh, G. P. Geba, and N. Molfino, “Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma,” European Respiratory Review, vol. 19, no. 115, pp. 46–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. J. Coyle, G. Le Gros, C. Bertrand et al., “Interleukin-4 is required for the induction of lung Th2 mucosal immunity,” American journal of respiratory cell and molecular biology, vol. 13, no. 1, pp. 54–59, 1995. View at Scopus
  71. D. A. Swart, P. M. Anders-Bartholo, and J. E. Tocker, “Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice,” Journal of Allergy and Clinical Immunology, vol. 121, no. 2, p. S267, 2008.
  72. J. W. Steinke, “Anti-interleukin-4 therapy,” Immunology and Allergy Clinics of North America, vol. 24, no. 4, pp. 599–614, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Burmeister Getz, D. M. Fisher, and R. Fuller, “Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma,” Journal of Clinical Pharmacology, vol. 49, no. 9, pp. 1025–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Wenzel, D. Wilbraham, R. Fuller, E. B. Getz, and M. Longphre, “Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies,” Lancet, vol. 370, no. 9596, pp. 1422–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. R. E. Slager, B. A. Otulana, G. A. Hawkins et al., “IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist,” Journal of Allergy and Clinical Immunology, vol. 130, no. 2, pp. 516–522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Wenzel, L. Ford, D. Pearlman et al., “Dupilumab in persistent asthma with elevated eosinophil levels,” The New England Journal of Medicine, 2013. View at Publisher · View at Google Scholar
  77. G. M. Gauvreau, L.-P. Boulet, D. W. Cockcroft et al., “Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 8, pp. 1007–1014, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Corren, R. F. Lemanske Jr., N. A. Hanania et al., “Lebrikizumab treatment in adults with asthma,” The New England Journal of Medicine, vol. 365, no. 12, pp. 1088–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. K. Oh, R. Faggioni, F. Jin et al., “An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males,” British Journal of Clinical Pharmacology, vol. 69, no. 6, pp. 645–655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Piper, C. Brightling, R. Niven et al., “A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma,” European Respiratory Journal, vol. 41, no. 2, pp. 330–338, 2013.
  81. C. K. Oh, D. Raible, G. P. Geba, and N. A. Molfino, “Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma,” Inflammation and Allergy, vol. 10, no. 3, pp. 180–186, 2011. View at Scopus
  82. G. Cheng, M. Arima, K. Honda et al., “Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 3, pp. 409–416, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. J. M. Parker, C. K. Oh, C. LaForce et al., “Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma,” BMC Pulmonary Medicine, vol. 11, article 14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Yamashita, H. Tashimo, H. Ishida et al., “Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF),” Cellular Immunology, vol. 219, no. 2, pp. 92–97, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. E.-M. Krinner, T. Raum, S. Petsch et al., “A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF,” Molecular Immunology, vol. 44, no. 5, pp. 916–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Brightling, M. Berry, and Y. Amrani, “Targeting TNF-α: a novel therapeutic approach for asthma,” Journal of Allergy and Clinical Immunology, vol. 121, no. 1, pp. 5–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. M. A. Berry, B. Hargadon, M. Shelley et al., “Evidence of a role of tumor necrosis factor α in refractory asthma,” The New England Journal of Medicine, vol. 354, no. 7, pp. 697–708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. T. Holgate, M. Noonan, P. Chanez et al., “Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial,” European Respiratory Journal, vol. 37, no. 6, pp. 1352–1359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. E. M. Erin, B. R. Leaker, G. C. Nicholson et al., “The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 753–762, 2006.
  90. S. E. Wenzel, P. J. Barnes, E. R. Bleecker et al., “A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 7, pp. 549–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. P. W. Hellings, A. Kasran, Z. Liu et al., “Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 1, pp. 42–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Wakashin, K. Hirose, Y. Maezawa et al., “IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 10, pp. 1023–1032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. S. J. Park and Y. C. Lee, “Interleukin-17 regulation: an attractive therapeutic approach for asthma,” Respiratory Research, vol. 11, article 78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Tamachi, Y. Maezawa, K. Ikeda et al., “IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice,” Journal of Allergy and Clinical Immunology, vol. 118, no. 3, pp. 606–614, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Kearley, K. F. Buckland, S. A. Mathie, and C. M. Lloyd, “Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 9, pp. 772–781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Fujita, M. Kawaguchi, F. Kokubu et al., “Interleukin-33 induces interleukin-17F in bronchial epithelial cells,” Allergy, vol. 67, no. 6, pp. 744–750, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Shi, S.-W. Leu, F. Xu et al., “Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells,” Clinical Immunology, vol. 129, no. 2, pp. 202–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. J. J. Li, W. Wang, K. J. Baines et al., “IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages,” Journal of Immunology, vol. 185, no. 7, pp. 4401–4409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. E. A. Jacobsen, R. A. Helmers, J. J. Lee, and N. A. Lee, “The expanding role(s) of eosinophils in health and disease,” Blood, vol. 120, no. 19, pp. 3882–3890, 2012.
  100. V. Fabre, D. P. Beiting, S. K. Bliss et al., “Eosinophil deficiency compromises parasite survival in chronic nematode infection,” Journal of Immunology, vol. 182, no. 3, pp. 1577–1583, 2009. View at Scopus
  101. N. G. Gebreselassie, A. R. Moorhead, V. Fabre et al., “Eosinophils preserve parasitic nematode larvae by regulating local immunity,” Journal of Immunology, vol. 188, no. 1, pp. 417–425, 2012. View at Publisher · View at Google Scholar · View at Scopus